Suppr超能文献

新旧氟喹诺酮类药物的作用机制及耐药性

Mechanisms of action and resistance of older and newer fluoroquinolones.

作者信息

Hooper D C

机构信息

Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114-2696, USA.

出版信息

Clin Infect Dis. 2000 Aug;31 Suppl 2:S24-8. doi: 10.1086/314056.

Abstract

The fluoroquinolones interact with 2 bacterial targets, the related enzymes DNA gyrase and topoisomerase IV, both of which are involved in DNA replication. Quinolones form complexes of these enzymes with DNA, complexes that block movement of the DNA-replication fork and thereby inhibit DNA replication. Many older quinolones differ in their relative activities against gyrase and topoisomerase IV in a bacterial cell, having greater potency against gyrase than against topoisomerase IV in many gram-negative bacteria and greater potency against topoisomerase IV than against gyrase in many gram-positive bacteria. Several newer quinolones appear to have more closely balanced activity against these enzymes. Resistance to fluoroquinolones occurs as a result of mutational amino acid substitutions in the subunits of the more sensitive (or primary-target) enzyme within the cell. If, however, both enzymes are similarly susceptible to a fluoroquinolone, then the level of resistance caused by a primary-target mutation may be low and may be limited by the sensitivity of the secondary target. Fluoroquinolones also differ in the extent to which common bacterial multidrug efflux pumps affect their activity, with some compounds being unaffected by resistance mechanisms because of overexpression of such pumps. Newer fluoroquinolone interaction with dual targets and avoidance of efflux-resistance mechanisms may each contribute to the lower frequencies of selection of resistant mutants in the laboratory.

摘要

氟喹诺酮类药物作用于两个细菌靶点,即相关酶DNA回旋酶和拓扑异构酶IV,这两种酶均参与DNA复制。喹诺酮类药物使这些酶与DNA形成复合物,这种复合物会阻碍DNA复制叉的移动,从而抑制DNA复制。许多较老的喹诺酮类药物在细菌细胞中对回旋酶和拓扑异构酶IV的相对活性有所不同,在许多革兰氏阴性菌中对回旋酶的效力比对拓扑异构酶IV更强,而在许多革兰氏阳性菌中对拓扑异构酶IV的效力比对回旋酶更强。几种较新的喹诺酮类药物似乎对这些酶具有更为平衡的活性。对氟喹诺酮类药物的耐药性是由于细胞内较敏感(或主要靶点)酶的亚基发生氨基酸突变取代所致。然而,如果两种酶对氟喹诺酮类药物同样敏感,那么主要靶点突变引起的耐药水平可能较低,并且可能受到次要靶点敏感性的限制。氟喹诺酮类药物在常见细菌多药外排泵影响其活性的程度方面也存在差异,一些化合物不会受到此类泵过度表达所产生的耐药机制的影响。较新的氟喹诺酮类药物与双重靶点的相互作用以及对外排耐药机制的规避,可能各自导致实验室中耐药突变体选择频率较低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验